182 related articles for article (PubMed ID: 18331443)
1. Calcineurin inhibitors and post-transplant weight gain.
Ersoy A; Baran B; Ersoy C; Kahvecioglu S; Akdag I
Nephrology (Carlton); 2008 Oct; 13(5):433-9. PubMed ID: 18331443
[TBL] [Abstract][Full Text] [Related]
2. The influence of calcineurin inhibitors on pulse wave velocity in renal transplant recipients.
Strózecki P; Adamowicz A; Włodarczyk Z; Manitius J
Ren Fail; 2007; 29(6):679-84. PubMed ID: 17763162
[TBL] [Abstract][Full Text] [Related]
3. High body mass index and posttransplant weight gain are not risk factors for kidney graft and patient outcome.
Marcén R; Fernández A; Pascual J; Teruel JL; Villafruela JJ; Rodriguez N; Martins J; Burgos FJ; Ortuño J
Transplant Proc; 2007 Sep; 39(7):2205-7. PubMed ID: 17889138
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
5. Weight gain and obesity after liver transplantation.
Richards J; Gunson B; Johnson J; Neuberger J
Transpl Int; 2005 Apr; 18(4):461-6. PubMed ID: 15773968
[TBL] [Abstract][Full Text] [Related]
6. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus.
Sinha MD; MacLeod R; Rigby E; Clark AG
Nephrol Dial Transplant; 2006 Jul; 21(7):1848-54. PubMed ID: 16311257
[TBL] [Abstract][Full Text] [Related]
9. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
10. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
[TBL] [Abstract][Full Text] [Related]
11. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
Deleuze S; Garrigue V; Delmas S; Chong G; Swarcz I; Cristol JP; Mourad G
Transplant Proc; 2006 Sep; 38(7):2311-3. PubMed ID: 16980075
[TBL] [Abstract][Full Text] [Related]
12. Diabetes mellitus after kidney transplantation: a French multicentre observational study.
Kamar N; Mariat C; Delahousse M; Dantal J; Al Najjar A; Cassuto E; Lefrançois N; Cointault O; Touchard G; Villemain F; Di Giambattista F; Benhamou PY;
Nephrol Dial Transplant; 2007 Jul; 22(7):1986-93. PubMed ID: 17400559
[TBL] [Abstract][Full Text] [Related]
13. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens.
Law YM; Yim R; Agatisa P; Boyle GJ; Miller SA; Lawrence K; Webber SA
J Heart Lung Transplant; 2006 Mar; 25(3):276-82. PubMed ID: 16507419
[TBL] [Abstract][Full Text] [Related]
14. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients.
Bozkaya G; Nart A; Uslu A; Onman T; Aykas A; Doğan M; Karaca B
Transplant Proc; 2008; 40(1):151-5. PubMed ID: 18261573
[TBL] [Abstract][Full Text] [Related]
15. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients.
Gallon L; Akalin E; Lynch P; Rothberg L; Parker M; Schiano T; Abecassis M; Murphy B
Transplantation; 2006 Feb; 81(3):463-8. PubMed ID: 16477235
[TBL] [Abstract][Full Text] [Related]
16. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression.
Martínez-Castelao A; Sarrias X; Bestard O; Gil-Vernet S; Serón D; Cruzado JM; Moreso F; Díez-Noguera A; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3788-90. PubMed ID: 16386539
[TBL] [Abstract][Full Text] [Related]
17. Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy.
van den Ham EC; Kooman JP; Christiaans MH; Nieman FH; van Hooff JP
Transpl Int; 2003 May; 16(5):300-6. PubMed ID: 12759720
[TBL] [Abstract][Full Text] [Related]
18. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial.
Meier M; Nitschke M; Weidtmann B; Jabs WJ; Wong W; Suefke S; Steinhoff J; Fricke L
Transplantation; 2006 Apr; 81(7):1035-40. PubMed ID: 16612281
[TBL] [Abstract][Full Text] [Related]
19. Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus.
Lauzurica R; Pastor MC; Bayes B; Malumbres S; Homs M; Llopis MA; Bonet J; Romero R
Transplant Proc; 2007 Sep; 39(7):2170-2. PubMed ID: 17889127
[TBL] [Abstract][Full Text] [Related]
20. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
